Mitomycin C use in pterygium surgery reduces the recurrence rate, suppressingangiogenesis and fibroblast proliferation, inhibiting NLRP3/caspase-1 pathway activationand the expression of inflammatory factors such as TGF-β1, VEGF, andIL-6(2-4). The gene discussed is NLRP3; the disease is pterygium.